A new clinical study will enroll about 500 African-Americans who have asthma to examine how they react to therapies and to explore the role of genetics in determining asthma treatment response. African-Americans have been found to suffer higher rates of serious asthma attacks, hospitalizations, and asthma-related deaths than whites.
The Best African American Response to Asthma Drugs (BARD) study is a multicenter clinical trial that will take place at 30 sites across 14 states. BARD will seek to assess the efficacy of various doses of inhaled corticosteroids (ICS) used with or without the addition of a long-acting beta agonist (LABA). Multiple combinations of medications and dosing regimens will be compared to assess therapeutic response. Further, BARD will examine whether children and adults respond similarly to the same treatment and see how genes may impact their response.
ICS is known to reduce inflammation and help control asthma in the long-term and LABAs act by relaxing tight airway muscles.
The BARD study began enrolling patients on February 10th and is supported by the National Heart, Lung, and Blood Institute of the National Institute of Health.
For more information call (717) 531-3663 or visit AsthmaNetResearch.org.